WO2023085300A1 - 優れた溶出性を有する医薬組成物 - Google Patents
優れた溶出性を有する医薬組成物 Download PDFInfo
- Publication number
- WO2023085300A1 WO2023085300A1 PCT/JP2022/041656 JP2022041656W WO2023085300A1 WO 2023085300 A1 WO2023085300 A1 WO 2023085300A1 JP 2022041656 W JP2022041656 W JP 2022041656W WO 2023085300 A1 WO2023085300 A1 WO 2023085300A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- pharmaceutical composition
- film
- granules
- tablets
- composition according
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 53
- 238000010828 elution Methods 0.000 title abstract description 6
- SSDRNUPMYCFXGM-UYPAYLBCSA-N ClC1=CC(=C(C2=C1O[C@](O2)(C)[C@@H]1CC[C@H](CC1)N(C)C)C)C(=O)NCC=1C(NC(=CC=1C)C)=O Chemical compound ClC1=CC(=C(C2=C1O[C@](O2)(C)[C@@H]1CC[C@H](CC1)N(C)C)C)C(=O)NCC=1C(NC(=CC=1C)C)=O SSDRNUPMYCFXGM-UYPAYLBCSA-N 0.000 claims abstract description 27
- 229940121348 valemetostat Drugs 0.000 claims abstract description 27
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 claims abstract description 24
- 229920002785 Croscarmellose sodium Polymers 0.000 claims abstract description 18
- 229960001681 croscarmellose sodium Drugs 0.000 claims abstract description 18
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 claims abstract description 18
- 150000003839 salts Chemical class 0.000 claims abstract description 15
- 229920003109 sodium starch glycolate Polymers 0.000 claims abstract description 15
- 239000008109 sodium starch glycolate Substances 0.000 claims abstract description 15
- 229940079832 sodium starch glycolate Drugs 0.000 claims abstract description 15
- 239000003826 tablet Substances 0.000 claims description 93
- 239000007888 film coating Substances 0.000 claims description 43
- 238000009501 film coating Methods 0.000 claims description 43
- 239000007941 film coated tablet Substances 0.000 claims description 33
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 24
- 239000001913 cellulose Substances 0.000 claims description 22
- 235000010980 cellulose Nutrition 0.000 claims description 21
- 229920002678 cellulose Polymers 0.000 claims description 21
- 229920000881 Modified starch Polymers 0.000 claims description 20
- 239000000314 lubricant Substances 0.000 claims description 15
- 239000004372 Polyvinyl alcohol Substances 0.000 claims description 11
- 229920002451 polyvinyl alcohol Polymers 0.000 claims description 11
- 229920001577 copolymer Polymers 0.000 claims description 9
- SMZOUWXMTYCWNB-UHFFFAOYSA-N 2-(2-methoxy-5-methylphenyl)ethanamine Chemical compound COC1=CC=C(C)C=C1CCN SMZOUWXMTYCWNB-UHFFFAOYSA-N 0.000 claims description 6
- NIXOWILDQLNWCW-UHFFFAOYSA-N 2-Propenoic acid Natural products OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 claims description 6
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims description 5
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims description 5
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims description 5
- 229960003943 hypromellose Drugs 0.000 claims description 5
- JSBKGJUYSLVFPF-WJQUPPJOSA-N Cc1ccc(cc1)S(O)(=O)=O.CN(C)[C@H]1CC[C@@H](CC1)[C@@]1(C)Oc2c(O1)c(C)c(cc2Cl)C(=O)NCc1c(C)cc(C)[nH]c1=O Chemical compound Cc1ccc(cc1)S(O)(=O)=O.CN(C)[C@H]1CC[C@@H](CC1)[C@@]1(C)Oc2c(O1)c(C)c(cc2Cl)C(=O)NCc1c(C)cc(C)[nH]c1=O JSBKGJUYSLVFPF-WJQUPPJOSA-N 0.000 abstract description 5
- 239000008187 granular material Substances 0.000 description 63
- 238000000034 method Methods 0.000 description 42
- 238000004090 dissolution Methods 0.000 description 30
- 238000007922 dissolution test Methods 0.000 description 23
- 239000011812 mixed powder Substances 0.000 description 22
- 239000011248 coating agent Substances 0.000 description 20
- 238000000576 coating method Methods 0.000 description 20
- 230000000052 comparative effect Effects 0.000 description 20
- 239000003795 chemical substances by application Substances 0.000 description 19
- 239000000843 powder Substances 0.000 description 17
- 238000013112 stability test Methods 0.000 description 16
- 238000007906 compression Methods 0.000 description 12
- 230000006835 compression Effects 0.000 description 12
- 239000004570 mortar (masonry) Substances 0.000 description 11
- 239000002775 capsule Substances 0.000 description 10
- 238000003860 storage Methods 0.000 description 10
- 239000003814 drug Substances 0.000 description 9
- 238000002156 mixing Methods 0.000 description 9
- RMAQACBXLXPBSY-UHFFFAOYSA-N silicic acid Chemical compound O[Si](O)(O)O RMAQACBXLXPBSY-UHFFFAOYSA-N 0.000 description 9
- 235000012239 silicon dioxide Nutrition 0.000 description 9
- 102100038970 Histone-lysine N-methyltransferase EZH2 Human genes 0.000 description 8
- 101000882127 Homo sapiens Histone-lysine N-methyltransferase EZH2 Proteins 0.000 description 8
- 229920002472 Starch Polymers 0.000 description 8
- 229940079593 drug Drugs 0.000 description 8
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 8
- -1 sucrose fatty acid esters Chemical class 0.000 description 8
- 238000002835 absorbance Methods 0.000 description 7
- 239000004480 active ingredient Substances 0.000 description 7
- 239000000654 additive Substances 0.000 description 7
- MVPICKVDHDWCJQ-UHFFFAOYSA-N ethyl 3-pyrrolidin-1-ylpropanoate Chemical compound CCOC(=O)CCN1CCCC1 MVPICKVDHDWCJQ-UHFFFAOYSA-N 0.000 description 7
- 229940045902 sodium stearyl fumarate Drugs 0.000 description 7
- 239000012085 test solution Substances 0.000 description 7
- 238000012360 testing method Methods 0.000 description 7
- 238000000870 ultraviolet spectroscopy Methods 0.000 description 7
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 6
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 6
- 239000007884 disintegrant Substances 0.000 description 6
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 6
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 6
- JEIPFZHSYJVQDO-UHFFFAOYSA-N iron(III) oxide Inorganic materials O=[Fe]O[Fe]=O JEIPFZHSYJVQDO-UHFFFAOYSA-N 0.000 description 6
- YOBAEOGBNPPUQV-UHFFFAOYSA-N iron;trihydrate Chemical compound O.O.O.[Fe].[Fe] YOBAEOGBNPPUQV-UHFFFAOYSA-N 0.000 description 6
- 239000000203 mixture Substances 0.000 description 6
- 229920003023 plastic Polymers 0.000 description 6
- 239000004033 plastic Substances 0.000 description 6
- 239000008107 starch Substances 0.000 description 6
- 229940032147 starch Drugs 0.000 description 6
- 235000019698 starch Nutrition 0.000 description 6
- 101001028782 Homo sapiens Histone-lysine N-methyltransferase EZH1 Proteins 0.000 description 5
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 5
- 229930006000 Sucrose Natural products 0.000 description 5
- 239000011230 binding agent Substances 0.000 description 5
- FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 description 5
- 235000013312 flour Nutrition 0.000 description 5
- 238000005469 granulation Methods 0.000 description 5
- 230000003179 granulation Effects 0.000 description 5
- 238000005259 measurement Methods 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 239000000454 talc Substances 0.000 description 5
- 229910052623 talc Inorganic materials 0.000 description 5
- 229940033134 talc Drugs 0.000 description 5
- 229950004288 tosilate Drugs 0.000 description 5
- 229920002261 Corn starch Polymers 0.000 description 4
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 4
- 241000209140 Triticum Species 0.000 description 4
- 235000021307 Triticum Nutrition 0.000 description 4
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 description 4
- 238000000748 compression moulding Methods 0.000 description 4
- 238000009472 formulation Methods 0.000 description 4
- 238000009775 high-speed stirring Methods 0.000 description 4
- 239000001341 hydroxy propyl starch Substances 0.000 description 4
- 235000013828 hydroxypropyl starch Nutrition 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 235000019359 magnesium stearate Nutrition 0.000 description 4
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 4
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 4
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 4
- 239000007787 solid Substances 0.000 description 4
- 239000005720 sucrose Substances 0.000 description 4
- OGIDPMRJRNCKJF-UHFFFAOYSA-N titanium oxide Inorganic materials [Ti]=O OGIDPMRJRNCKJF-UHFFFAOYSA-N 0.000 description 4
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 3
- SSDRNUPMYCFXGM-ZZHSESOFSA-N CN(C)C1CCC(CC1)[C@@]1(C)Oc2c(O1)c(C)c(cc2Cl)C(=O)NCc1c(C)cc(C)[nH]c1=O Chemical compound CN(C)C1CCC(CC1)[C@@]1(C)Oc2c(O1)c(C)c(cc2Cl)C(=O)NCc1c(C)cc(C)[nH]c1=O SSDRNUPMYCFXGM-ZZHSESOFSA-N 0.000 description 3
- 229920000623 Cellulose acetate phthalate Polymers 0.000 description 3
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 3
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 3
- 241000698776 Duma Species 0.000 description 3
- 108010000597 Polycomb Repressive Complex 2 Proteins 0.000 description 3
- 102000002272 Polycomb Repressive Complex 2 Human genes 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 239000004373 Pullulan Substances 0.000 description 3
- 229920001218 Pullulan Polymers 0.000 description 3
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 3
- YKTSYUJCYHOUJP-UHFFFAOYSA-N [O--].[Al+3].[Al+3].[O-][Si]([O-])([O-])[O-] Chemical compound [O--].[Al+3].[Al+3].[O-][Si]([O-])([O-])[O-] YKTSYUJCYHOUJP-UHFFFAOYSA-N 0.000 description 3
- 229910052782 aluminium Inorganic materials 0.000 description 3
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 3
- 229910000389 calcium phosphate Inorganic materials 0.000 description 3
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical class [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 3
- 229940081734 cellulose acetate phthalate Drugs 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 239000003086 colorant Substances 0.000 description 3
- 235000019700 dicalcium phosphate Nutrition 0.000 description 3
- 235000014113 dietary fatty acids Nutrition 0.000 description 3
- 238000007907 direct compression Methods 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 238000011156 evaluation Methods 0.000 description 3
- 239000000194 fatty acid Substances 0.000 description 3
- 229930195729 fatty acid Natural products 0.000 description 3
- 238000011049 filling Methods 0.000 description 3
- 239000000796 flavoring agent Substances 0.000 description 3
- 239000012530 fluid Substances 0.000 description 3
- 235000013355 food flavoring agent Nutrition 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- AZVARJHZBXHUSO-DZQVEHCYSA-N methyl (1R,4R,12S)-4-methyl-3,7-dioxo-10-(5,6,7-trimethoxy-1H-indole-2-carbonyl)-5,10-diazatetracyclo[7.4.0.01,12.02,6]trideca-2(6),8-diene-4-carboxylate Chemical compound COC1=C(OC)C(OC)=C2NC(C(=O)N3C[C@H]4C[C@]44C5=C(C(C=C43)=O)N[C@@](C5=O)(C)C(=O)OC)=CC2=C1 AZVARJHZBXHUSO-DZQVEHCYSA-N 0.000 description 3
- 235000019426 modified starch Nutrition 0.000 description 3
- 239000002245 particle Substances 0.000 description 3
- 239000004014 plasticizer Substances 0.000 description 3
- 229940088417 precipitated calcium carbonate Drugs 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 235000019423 pullulan Nutrition 0.000 description 3
- 239000000600 sorbitol Substances 0.000 description 3
- 235000010356 sorbitol Nutrition 0.000 description 3
- 239000000758 substrate Substances 0.000 description 3
- URAYPUMNDPQOKB-UHFFFAOYSA-N triacetin Chemical compound CC(=O)OCC(OC(C)=O)COC(C)=O URAYPUMNDPQOKB-UHFFFAOYSA-N 0.000 description 3
- WRMNZCZEMHIOCP-UHFFFAOYSA-N 2-phenylethanol Chemical compound OCCC1=CC=CC=C1 WRMNZCZEMHIOCP-UHFFFAOYSA-N 0.000 description 2
- 244000215068 Acacia senegal Species 0.000 description 2
- 229920002126 Acrylic acid copolymer Polymers 0.000 description 2
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- 229920000084 Gum arabic Polymers 0.000 description 2
- 108010033040 Histones Proteins 0.000 description 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 2
- 235000019759 Maize starch Nutrition 0.000 description 2
- CERQOIWHTDAKMF-UHFFFAOYSA-N Methacrylic acid Chemical compound CC(=C)C(O)=O CERQOIWHTDAKMF-UHFFFAOYSA-N 0.000 description 2
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 2
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 240000007594 Oryza sativa Species 0.000 description 2
- 235000007164 Oryza sativa Nutrition 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- 230000005856 abnormality Effects 0.000 description 2
- 235000010489 acacia gum Nutrition 0.000 description 2
- 239000000205 acacia gum Substances 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- WNLRTRBMVRJNCN-UHFFFAOYSA-N adipic acid Chemical compound OC(=O)CCCCC(O)=O WNLRTRBMVRJNCN-UHFFFAOYSA-N 0.000 description 2
- 238000013019 agitation Methods 0.000 description 2
- HZVVJJIYJKGMFL-UHFFFAOYSA-N almasilate Chemical compound O.[Mg+2].[Al+3].[Al+3].O[Si](O)=O.O[Si](O)=O HZVVJJIYJKGMFL-UHFFFAOYSA-N 0.000 description 2
- BWZOPYPOZJBVLQ-UHFFFAOYSA-K aluminium glycinate Chemical compound O[Al+]O.NCC([O-])=O BWZOPYPOZJBVLQ-UHFFFAOYSA-K 0.000 description 2
- 229920003144 amino alkyl methacrylate copolymer Polymers 0.000 description 2
- 229960000686 benzalkonium chloride Drugs 0.000 description 2
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 239000001506 calcium phosphate Substances 0.000 description 2
- 229960001714 calcium phosphate Drugs 0.000 description 2
- 235000011010 calcium phosphates Nutrition 0.000 description 2
- 235000013539 calcium stearate Nutrition 0.000 description 2
- 239000008116 calcium stearate Substances 0.000 description 2
- 229940095672 calcium sulfate Drugs 0.000 description 2
- 235000011132 calcium sulphate Nutrition 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 239000001768 carboxy methyl cellulose Substances 0.000 description 2
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 description 2
- OSASVXMJTNOKOY-UHFFFAOYSA-N chlorobutanol Chemical compound CC(C)(O)C(Cl)(Cl)Cl OSASVXMJTNOKOY-UHFFFAOYSA-N 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 239000008120 corn starch Substances 0.000 description 2
- 229960000913 crospovidone Drugs 0.000 description 2
- XLIDPNGFCHXNGX-UHFFFAOYSA-N dialuminum;oxygen(2-);silicon(4+) Chemical compound [O-2].[O-2].[O-2].[O-2].[O-2].[Al+3].[Al+3].[Si+4] XLIDPNGFCHXNGX-UHFFFAOYSA-N 0.000 description 2
- 229940015826 dihydroxyaluminum aminoacetate Drugs 0.000 description 2
- POULHZVOKOAJMA-UHFFFAOYSA-N dodecanoic acid Chemical compound CCCCCCCCCCCC(O)=O POULHZVOKOAJMA-UHFFFAOYSA-N 0.000 description 2
- 229940126534 drug product Drugs 0.000 description 2
- 239000003995 emulsifying agent Substances 0.000 description 2
- 235000012732 erythrosine Nutrition 0.000 description 2
- 235000013773 glyceryl triacetate Nutrition 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- WTFXARWRTYJXII-UHFFFAOYSA-N iron(2+);iron(3+);oxygen(2-) Chemical compound [O-2].[O-2].[O-2].[O-2].[Fe+2].[Fe+3].[Fe+3] WTFXARWRTYJXII-UHFFFAOYSA-N 0.000 description 2
- SZVJSHCCFOBDDC-UHFFFAOYSA-N iron(II,III) oxide Inorganic materials O=[Fe]O[Fe]O[Fe]=O SZVJSHCCFOBDDC-UHFFFAOYSA-N 0.000 description 2
- 229940031703 low substituted hydroxypropyl cellulose Drugs 0.000 description 2
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 2
- 239000001095 magnesium carbonate Substances 0.000 description 2
- 229910000021 magnesium carbonate Inorganic materials 0.000 description 2
- HCWCAKKEBCNQJP-UHFFFAOYSA-N magnesium orthosilicate Chemical compound [Mg+2].[Mg+2].[O-][Si]([O-])([O-])[O-] HCWCAKKEBCNQJP-UHFFFAOYSA-N 0.000 description 2
- 239000000395 magnesium oxide Substances 0.000 description 2
- CPLXHLVBOLITMK-UHFFFAOYSA-N magnesium oxide Inorganic materials [Mg]=O CPLXHLVBOLITMK-UHFFFAOYSA-N 0.000 description 2
- 239000000391 magnesium silicate Substances 0.000 description 2
- 235000019792 magnesium silicate Nutrition 0.000 description 2
- 229910052919 magnesium silicate Inorganic materials 0.000 description 2
- AXZKOIWUVFPNLO-UHFFFAOYSA-N magnesium;oxygen(2-) Chemical compound [O-2].[Mg+2] AXZKOIWUVFPNLO-UHFFFAOYSA-N 0.000 description 2
- 230000000873 masking effect Effects 0.000 description 2
- 230000011987 methylation Effects 0.000 description 2
- 238000007069 methylation reaction Methods 0.000 description 2
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 2
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 2
- 239000008108 microcrystalline cellulose Substances 0.000 description 2
- 229940016286 microcrystalline cellulose Drugs 0.000 description 2
- 239000000825 pharmaceutical preparation Substances 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 235000013809 polyvinylpolypyrrolidone Nutrition 0.000 description 2
- 229920000523 polyvinylpolypyrrolidone Polymers 0.000 description 2
- 229920001592 potato starch Polymers 0.000 description 2
- 229920003124 powdered cellulose Polymers 0.000 description 2
- 235000019814 powdered cellulose Nutrition 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 2
- 238000010298 pulverizing process Methods 0.000 description 2
- 235000009566 rice Nutrition 0.000 description 2
- 229940100486 rice starch Drugs 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 150000003467 sulfuric acid derivatives Chemical class 0.000 description 2
- 238000013268 sustained release Methods 0.000 description 2
- 239000012730 sustained-release form Substances 0.000 description 2
- 229960005196 titanium dioxide Drugs 0.000 description 2
- 229960002622 triacetin Drugs 0.000 description 2
- 235000019731 tricalcium phosphate Nutrition 0.000 description 2
- 239000010497 wheat germ oil Substances 0.000 description 2
- 229940100445 wheat starch Drugs 0.000 description 2
- NOOLISFMXDJSKH-UTLUCORTSA-N (+)-Neomenthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@@H]1O NOOLISFMXDJSKH-UTLUCORTSA-N 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- QTWJRLJHJPIABL-UHFFFAOYSA-N 2-methylphenol;3-methylphenol;4-methylphenol Chemical compound CC1=CC=C(O)C=C1.CC1=CC=CC(O)=C1.CC1=CC=CC=C1O QTWJRLJHJPIABL-UHFFFAOYSA-N 0.000 description 1
- UBVSIAHUTXHQTD-UHFFFAOYSA-N 2-n-(4-bromophenyl)-1,3,5-triazine-2,4-diamine Chemical compound NC1=NC=NC(NC=2C=CC(Br)=CC=2)=N1 UBVSIAHUTXHQTD-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- WSVLPVUVIUVCRA-KPKNDVKVSA-N Alpha-lactose monohydrate Chemical compound O.O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O WSVLPVUVIUVCRA-KPKNDVKVSA-N 0.000 description 1
- 108010011485 Aspartame Proteins 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 108010077544 Chromatin Proteins 0.000 description 1
- 235000005979 Citrus limon Nutrition 0.000 description 1
- 244000131522 Citrus pyriformis Species 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- NOOLISFMXDJSKH-UHFFFAOYSA-N DL-menthol Natural products CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 description 1
- 239000004287 Dehydroacetic acid Substances 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 244000024675 Eruca sativa Species 0.000 description 1
- 235000014755 Eruca sativa Nutrition 0.000 description 1
- JIGUQPWFLRLWPJ-UHFFFAOYSA-N Ethyl acrylate Chemical compound CCOC(=O)C=C JIGUQPWFLRLWPJ-UHFFFAOYSA-N 0.000 description 1
- 239000001856 Ethyl cellulose Substances 0.000 description 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 239000004354 Hydroxyethyl cellulose Substances 0.000 description 1
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 description 1
- 229920001479 Hydroxyethyl methyl cellulose Polymers 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 239000005639 Lauric acid Substances 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- VVQNEPGJFQJSBK-UHFFFAOYSA-N Methyl methacrylate Chemical compound COC(=O)C(C)=C VVQNEPGJFQJSBK-UHFFFAOYSA-N 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 229920001214 Polysorbate 60 Polymers 0.000 description 1
- 229920001800 Shellac Polymers 0.000 description 1
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- OIQPTROHQCGFEF-QIKYXUGXSA-L Sunset Yellow FCF Chemical compound [Na+].[Na+].OC1=CC=C2C=C(S([O-])(=O)=O)C=CC2=C1\N=N\C1=CC=C(S([O-])(=O)=O)C=C1 OIQPTROHQCGFEF-QIKYXUGXSA-L 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- DOOTYTYQINUNNV-UHFFFAOYSA-N Triethyl citrate Chemical compound CCOC(=O)CC(O)(C(=O)OCC)CC(=O)OCC DOOTYTYQINUNNV-UHFFFAOYSA-N 0.000 description 1
- XTXRWKRVRITETP-UHFFFAOYSA-N Vinyl acetate Chemical compound CC(=O)OC=C XTXRWKRVRITETP-UHFFFAOYSA-N 0.000 description 1
- 235000019888 Vivapur Nutrition 0.000 description 1
- HERJJROLHRDFEX-UHFFFAOYSA-N [AlH3].[Si](O)(O)(O)O Chemical compound [AlH3].[Si](O)(O)(O)O HERJJROLHRDFEX-UHFFFAOYSA-N 0.000 description 1
- DHKHKXVYLBGOIT-UHFFFAOYSA-N acetaldehyde Diethyl Acetal Natural products CCOC(C)OCC DHKHKXVYLBGOIT-UHFFFAOYSA-N 0.000 description 1
- 150000001252 acrylic acid derivatives Chemical class 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 239000001361 adipic acid Substances 0.000 description 1
- 235000011037 adipic acid Nutrition 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 150000005215 alkyl ethers Chemical class 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
- 125000000129 anionic group Chemical group 0.000 description 1
- 230000002421 anti-septic effect Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 229940064004 antiseptic throat preparations Drugs 0.000 description 1
- 239000000605 aspartame Substances 0.000 description 1
- 235000010357 aspartame Nutrition 0.000 description 1
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 1
- 229960003438 aspartame Drugs 0.000 description 1
- 239000012752 auxiliary agent Substances 0.000 description 1
- 235000013871 bee wax Nutrition 0.000 description 1
- 239000012166 beeswax Substances 0.000 description 1
- 239000000440 bentonite Substances 0.000 description 1
- 229910000278 bentonite Inorganic materials 0.000 description 1
- SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 1
- 235000019445 benzyl alcohol Nutrition 0.000 description 1
- 229960004217 benzyl alcohol Drugs 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- YYRMJZQKEFZXMX-UHFFFAOYSA-L calcium bis(dihydrogenphosphate) Chemical compound [Ca+2].OP(O)([O-])=O.OP(O)([O-])=O YYRMJZQKEFZXMX-UHFFFAOYSA-L 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 229940062672 calcium dihydrogen phosphate Drugs 0.000 description 1
- 239000000378 calcium silicate Substances 0.000 description 1
- 229910052918 calcium silicate Inorganic materials 0.000 description 1
- OYACROKNLOSFPA-UHFFFAOYSA-N calcium;dioxido(oxo)silane Chemical compound [Ca+2].[O-][Si]([O-])=O OYACROKNLOSFPA-UHFFFAOYSA-N 0.000 description 1
- 150000004649 carbonic acid derivatives Chemical class 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 229920003123 carboxymethyl cellulose sodium Polymers 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 229940105329 carboxymethylcellulose Drugs 0.000 description 1
- 229940084030 carboxymethylcellulose calcium Drugs 0.000 description 1
- 229940063834 carboxymethylcellulose sodium Drugs 0.000 description 1
- 239000003093 cationic surfactant Substances 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 229960004926 chlorobutanol Drugs 0.000 description 1
- 210000003483 chromatin Anatomy 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 239000007931 coated granule Substances 0.000 description 1
- 239000008119 colloidal silica Substances 0.000 description 1
- 230000001447 compensatory effect Effects 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 229930003836 cresol Natural products 0.000 description 1
- 229940061632 dehydroacetic acid Drugs 0.000 description 1
- 235000019258 dehydroacetic acid Nutrition 0.000 description 1
- PGRHXDWITVMQBC-UHFFFAOYSA-N dehydroacetic acid Natural products CC(=O)C1C(=O)OC(C)=CC1=O PGRHXDWITVMQBC-UHFFFAOYSA-N 0.000 description 1
- JEQRBTDTEKWZBW-UHFFFAOYSA-N dehydroacetic acid Chemical compound CC(=O)C1=C(O)OC(C)=CC1=O JEQRBTDTEKWZBW-UHFFFAOYSA-N 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- JAUGGEIKQIHSMF-UHFFFAOYSA-N dialuminum;dimagnesium;dioxido(oxo)silane;oxygen(2-);hydrate Chemical compound O.[O-2].[O-2].[Mg+2].[Mg+2].[Al+3].[Al+3].[O-][Si]([O-])=O.[O-][Si]([O-])=O.[O-][Si]([O-])=O JAUGGEIKQIHSMF-UHFFFAOYSA-N 0.000 description 1
- 125000004177 diethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 238000007908 dry granulation Methods 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- IINNWAYUJNWZRM-UHFFFAOYSA-L erythrosin B Chemical compound [Na+].[Na+].[O-]C(=O)C1=CC=CC=C1C1=C2C=C(I)C(=O)C(I)=C2OC2=C(I)C([O-])=C(I)C=C21 IINNWAYUJNWZRM-UHFFFAOYSA-L 0.000 description 1
- 239000004174 erythrosine Substances 0.000 description 1
- 229940011411 erythrosine Drugs 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
- 235000019325 ethyl cellulose Nutrition 0.000 description 1
- 229920001249 ethyl cellulose Polymers 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229940014259 gelatin Drugs 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 230000014509 gene expression Effects 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 239000001087 glyceryl triacetate Substances 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 1
- 229940031704 hydroxypropyl methylcellulose phthalate Drugs 0.000 description 1
- 229920003132 hydroxypropyl methylcellulose phthalate Polymers 0.000 description 1
- 229940071676 hydroxypropylcellulose Drugs 0.000 description 1
- 229920000639 hydroxypropylmethylcellulose acetate succinate Polymers 0.000 description 1
- 229960003988 indigo carmine Drugs 0.000 description 1
- KHLVKKOJDHCJMG-QDBORUFSSA-L indigo carmine Chemical compound [Na+].[Na+].N/1C2=CC=C(S([O-])(=O)=O)C=C2C(=O)C\1=C1/NC2=CC=C(S(=O)(=O)[O-])C=C2C1=O KHLVKKOJDHCJMG-QDBORUFSSA-L 0.000 description 1
- 235000012738 indigotine Nutrition 0.000 description 1
- 239000004179 indigotine Substances 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 229960001708 magnesium carbonate Drugs 0.000 description 1
- VTHJTEIRLNZDEV-UHFFFAOYSA-L magnesium dihydroxide Chemical compound [OH-].[OH-].[Mg+2] VTHJTEIRLNZDEV-UHFFFAOYSA-L 0.000 description 1
- 239000000347 magnesium hydroxide Substances 0.000 description 1
- 229910001862 magnesium hydroxide Inorganic materials 0.000 description 1
- 229960000869 magnesium oxide Drugs 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 229940041616 menthol Drugs 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 229910000000 metal hydroxide Inorganic materials 0.000 description 1
- 150000004692 metal hydroxides Chemical class 0.000 description 1
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- 229960002216 methylparaben Drugs 0.000 description 1
- 239000003094 microcapsule Substances 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 235000019691 monocalcium phosphate Nutrition 0.000 description 1
- 238000000465 moulding Methods 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 239000002736 nonionic surfactant Substances 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 239000008184 oral solid dosage form Substances 0.000 description 1
- 239000008012 organic excipient Substances 0.000 description 1
- PNJWIWWMYCMZRO-UHFFFAOYSA-N pent‐4‐en‐2‐one Natural products CC(=O)CC=C PNJWIWWMYCMZRO-UHFFFAOYSA-N 0.000 description 1
- 150000002989 phenols Chemical class 0.000 description 1
- 229940067107 phenylethyl alcohol Drugs 0.000 description 1
- 235000021317 phosphate Nutrition 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- XNGIFLGASWRNHJ-UHFFFAOYSA-L phthalate(2-) Chemical compound [O-]C(=O)C1=CC=CC=C1C([O-])=O XNGIFLGASWRNHJ-UHFFFAOYSA-L 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 229920001451 polypropylene glycol Polymers 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 description 1
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
- 229960003415 propylparaben Drugs 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 239000004208 shellac Substances 0.000 description 1
- ZLGIYFNHBLSMPS-ATJNOEHPSA-N shellac Chemical compound OCCCCCC(O)C(O)CCCCCCCC(O)=O.C1C23[C@H](C(O)=O)CCC2[C@](C)(CO)[C@@H]1C(C(O)=O)=C[C@@H]3O ZLGIYFNHBLSMPS-ATJNOEHPSA-N 0.000 description 1
- 229940113147 shellac Drugs 0.000 description 1
- 235000013874 shellac Nutrition 0.000 description 1
- 150000004760 silicates Chemical class 0.000 description 1
- NGHMEZWZOZEZOH-UHFFFAOYSA-N silicic acid;hydrate Chemical compound O.O[Si](O)(O)O NGHMEZWZOZEZOH-UHFFFAOYSA-N 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 229910052938 sodium sulfate Inorganic materials 0.000 description 1
- 235000011152 sodium sulphate Nutrition 0.000 description 1
- OKODKVMXHLUQSW-JITBQSAISA-M sodium;(e)-4-hydroxy-4-oxobut-2-enoate;octadecanoic acid Chemical compound [Na+].OC(=O)\C=C\C([O-])=O.CCCCCCCCCCCCCCCCCC(O)=O OKODKVMXHLUQSW-JITBQSAISA-M 0.000 description 1
- 239000007901 soft capsule Substances 0.000 description 1
- 239000004334 sorbic acid Substances 0.000 description 1
- 235000010199 sorbic acid Nutrition 0.000 description 1
- 229940075582 sorbic acid Drugs 0.000 description 1
- 239000012177 spermaceti Substances 0.000 description 1
- 229940084106 spermaceti Drugs 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 210000000130 stem cell Anatomy 0.000 description 1
- 239000006190 sub-lingual tablet Substances 0.000 description 1
- 238000009495 sugar coating Methods 0.000 description 1
- 235000012751 sunset yellow FCF Nutrition 0.000 description 1
- 239000004173 sunset yellow FCF Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 229920001059 synthetic polymer Polymers 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 235000012756 tartrazine Nutrition 0.000 description 1
- 239000004149 tartrazine Substances 0.000 description 1
- 229960000943 tartrazine Drugs 0.000 description 1
- UJMBCXLDXJUMFB-GLCFPVLVSA-K tartrazine Chemical compound [Na+].[Na+].[Na+].[O-]C(=O)C1=NN(C=2C=CC(=CC=2)S([O-])(=O)=O)C(=O)C1\N=N\C1=CC=C(S([O-])(=O)=O)C=C1 UJMBCXLDXJUMFB-GLCFPVLVSA-K 0.000 description 1
- RTKIYNMVFMVABJ-UHFFFAOYSA-L thimerosal Chemical compound [Na+].CC[Hg]SC1=CC=CC=C1C([O-])=O RTKIYNMVFMVABJ-UHFFFAOYSA-L 0.000 description 1
- 229940033663 thimerosal Drugs 0.000 description 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
- 239000001069 triethyl citrate Substances 0.000 description 1
- VMYFZRTXGLUXMZ-UHFFFAOYSA-N triethyl citrate Natural products CCOC(=O)C(O)(C(=O)OCC)C(=O)OCC VMYFZRTXGLUXMZ-UHFFFAOYSA-N 0.000 description 1
- 235000013769 triethyl citrate Nutrition 0.000 description 1
- UJMBCXLDXJUMFB-UHFFFAOYSA-K trisodium;5-oxo-1-(4-sulfonatophenyl)-4-[(4-sulfonatophenyl)diazenyl]-4h-pyrazole-3-carboxylate Chemical compound [Na+].[Na+].[Na+].[O-]C(=O)C1=NN(C=2C=CC(=CC=2)S([O-])(=O)=O)C(=O)C1N=NC1=CC=C(S([O-])(=O)=O)C=C1 UJMBCXLDXJUMFB-UHFFFAOYSA-K 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
- 238000005550 wet granulation Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4433—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with oxygen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Definitions
- the present invention relates to a pharmaceutical composition having excellent dissolution properties for valemetostat or a pharmaceutically acceptable salt thereof.
- Enhancerofzeste homologue 1/2 (EZH1/2) is the active center of polycomb repressive complex 2 (PRC2) that trimethylates histone H3K27.
- EZH1 and EZH2 complement each other's functions to maintain the intracellular epigenome. Inhibition of EZH2 leads to a decrease in H3K27 methylation levels throughout the cell, but the effect is limited by the compensatory effect of EZH1. By simultaneously inhibiting EZH1 and EZH2, methylation can be eliminated more effectively (Non-Patent Document 1). Abnormalities in PRC2 constituent factors have been shown to lead to abnormalities in cancer and stem cell function. is being actively studied as a new molecular target for cancer (Non-Patent Documents 2 and 3).
- Valemetostat and its pharmaceutically acceptable salts are known as EZH1/2 dual inhibitors (Patent Document 1).
- Valemetostat has the following structural formula:
- An object of the present invention is to provide a pharmaceutical composition with excellent dissolution properties for valemetostat or a pharmaceutically acceptable salt thereof, particularly valemetostat tosylate.
- valemetostat tosylate exhibits sufficient solubility under vigorous stirring, dissolution tests used to evaluate the dissolution of drugs from oral solid dosage forms, e.g. Dissolution test method Paddle method Under gentle agitation such as 50 revolutions per minute, the drug on the surface of the preparation changes to a translucent state and prevents the dissolution of the drug inside, resulting in a very low dissolution. This is because we found a problem that the dissolution rate expected from the solubility cannot be obtained. Since the effect of vigorous stirring cannot be expected in vivo, a pharmaceutical composition having sufficient dissolution property even in vivo is required.
- the present inventors have made extensive studies to solve the problem. As a result, it was found that a combination of valemetostat or a pharmaceutically acceptable salt thereof and one or more of croscarmellose sodium and sodium starch glycolate provides excellent dissolution. . Furthermore, the inventors have surprisingly found that a film-coated tablet retains excellent dissolution properties even after long-term storage, leading to the completion of the present invention.
- the present invention relates to the following (1) to (10).
- a pharmaceutical composition comprising valemetostat or a pharmaceutically acceptable salt thereof and at least one selected from croscarmellose sodium and sodium starch glycolate.
- the pharmaceutical composition according to (1) further comprising a water-insoluble excipient.
- the pharmaceutical composition according to (2) wherein the water-insoluble excipient is one or more selected from crystalline cellulose, partially pregelatinized starch, and pregelatinized starch.
- the pharmaceutical composition according to any one of (1) to (5) containing 5 to 45% by weight of sodium starch glycolate relative to the total weight of the pharmaceutical composition.
- the pharmaceutical composition according to any one of (1) to (6) further comprising one or more lubricants.
- the pharmaceutical composition according to any one of (1) to (7) which is a tablet.
- the pharmaceutical composition according to (8) which is a film-coated tablet.
- Valemetostat is a compound of formula (I) of the present invention, (2R)-7-chloro-2-[trans-4-(dimethylamino)cyclohexyl]-N-[(4,6-dimethyl -2-oxo-1,2-dihydropyridin-3-yl)methyl]-2,4-dimethyl-1,3-benzodioxole-5-carboxamide, valemetostat, or DS-3201a.
- Valemetostat can be manufactured, for example, according to the method described in Example 35 of WO2015/141616.
- WO2015/141616 is incorporated herein in its entirety by reference.
- valemetostat is most preferably (2R)-7-chloro-2-[trans-4-(dimethylamino)cyclohexyl]-N-[(4,6-dimethyl- 2-oxo-1,2-dihydropyridin-3-yl)methyl]-2,4-dimethyl-1,3-benzodioxole-5-carboxamide p-toluenesulfonate, balemetostat tosylate , or DS-3201b.
- Valemetostat and valemetostat tosylate are sometimes collectively referred to as DS-3201.
- the "sodium starch glycolate" used in the present invention may be any one that can be used as a pharmaceutical additive. Trademark) (manufactured by JRSPharma) and the like, preferably Explotab.
- the mixing ratio of sodium starch glycolate used in the present invention in the pharmaceutical composition is preferably 5 to 45% by mass with respect to the total mass of the pharmaceutical composition. More preferably, it is 5 to 30% by mass.
- excipients used in the present invention include sugar derivatives such as lactose, lactose hydrate, sucrose, glucose, mannitol or sorbitol; corn starch, corn starch granules, potato starch, pregelatinized starch.
- Excipient in addition, crospovidone, wheat germ oil, titanium oxide, magnesium oxide, talc, dihydroxyaluminum aminoacetate, magnesium carbonate, sodium stearyl fumarate, magnesium stearate and the like can be mentioned.
- the mixing ratio of excipients is not particularly limited as long as it complies with the present invention, and may be set as appropriate, for example, so as to improve the dissolution properties of the pharmaceutical composition of the present invention.
- water-insoluble excipient included in “excipient” means a water-insoluble excipient, such as carmellose sodium, crospovidone, magnesium aluminosilicate, silica Calcium phosphate, magnesium silicate, light anhydrous silicic acid, crystalline cellulose, crystalline cellulose/light anhydrous silicic acid, crystalline cellulose/carmellose sodium, powdered cellulose, pregelatinized starch, partially pregelatinized starch, synthetic aluminum silicate, synthetic silicic acid Aluminum, hydroxypropyl starch, crystalline cellulose, wheat flour, wheat starch, wheat germ powder, wheat germ oil, rice flour, rice starch, cellulose acetate phthalate, titanium oxide, magnesium oxide, dihydroxyaluminum aminoacetate, tribasic calcium phosphate, talc, carbonate Calcium, magnesium carbonate, precipitated calcium carbonate, natural aluminum silicate, maize starch, maize starch granules, potato starch, hydroxypropyl starch,
- the total mixing ratio of croscarmellose sodium, sodium starch glycolate and water-insoluble excipients used in the present invention in the pharmaceutical composition may be 10 to 90% by mass with respect to the total mass of the pharmaceutical composition. It may be 20 to 80% by mass, 30 to 70% by mass, or 45 to 70% by mass.
- the "crystalline cellulose" used in the present invention may be any material that can be used as a pharmaceutical additive, and can be used regardless of the particle size or bulk density.
- VIVAPUR registered trademark
- Ceolus registered trademark
- PH series manufactured by Asahi Kasei
- Ceolus registered trademark
- UF series manufactured by Asahi Kasei
- Ceolus registered trademark
- KG series manufactured by Asahi Kasei
- Ceolus KG series manufactured by Asahi Kasei
- the mixing ratio of the crystalline cellulose used in the present invention in the pharmaceutical composition is preferably 1 to 60% by mass with respect to the total mass of the pharmaceutical composition. More preferably, it is 19 to 55% by mass.
- the "partially pregelatinized starch” used in the present invention may be any one that can be used as a pharmaceutical additive.
- the blending ratio of the partially pregelatinized starch used in the present invention in the pharmaceutical composition is preferably 1 to 70% by mass relative to the total mass of the pharmaceutical composition. More preferably, it is 1 to 40% by mass.
- the "pregelatinized starch” used in the present invention may be any one that can be used as a pharmaceutical additive. Examples include Starch 1500G manufactured by Nippon Colorcon, SWELSTAR PD-1 manufactured by Asahi Kasei, etc. Starch 1500G manufactured by Nippon Colorcon is preferred. .
- the blending ratio of the pregelatinized starch used in the present invention in the pharmaceutical composition is preferably 1 to 70% by mass relative to the total mass of the pharmaceutical composition. More preferably, it is 1 to 40% by mass.
- the pharmaceutical composition of the present invention may further contain appropriate pharmaceutically acceptable lubricants, binders, emulsifiers, stabilizers, flavoring agents, colorants and disintegrants as necessary. and/or additives such as preservatives.
- binder examples include hydroxypropylcellulose, hypromellose, polyvinylpyrrolidone, polyethylene glycol, or compounds similar to the excipients described above. Hydroxypropyl cellulose is preferred.
- Emsifiers for use in the present invention include, for example, colloidal clays such as bentonite or Veegum; metal hydroxides such as magnesium hydroxide or aluminum hydroxide; anionic interfaces such as sodium lauryl sulfate or calcium stearate; active agents; cationic surfactants such as benzalkonium chloride; nonionic surfactants such as polyoxyethylene alkyl ethers, polyoxyethylene sorbitan fatty acid esters or sucrose fatty acid esters.
- colloidal clays such as bentonite or Veegum
- metal hydroxides such as magnesium hydroxide or aluminum hydroxide
- anionic interfaces such as sodium lauryl sulfate or calcium stearate
- active agents such as benzalkonium chloride
- nonionic surfactants such as polyoxyethylene alkyl ethers, polyoxyethylene sorbitan fatty acid esters or sucrose fatty acid esters.
- stabilizers used in the present invention include paraoxybenzoic acid esters such as methylparaben or propylparaben; alcohols such as chlorobutanol, benzyl alcohol or phenylethyl alcohol; benzalkonium chloride; phenol or cresol. phenols such as; thimerosal; dehydroacetic acid; sorbic acid and the like.
- flavoring agents used in the present invention include, for example, sweeteners such as sodium saccharin or aspartame; acidulants such as citric acid, malic acid or tartaric acid; flavoring agents such as menthol, lemon or orange. can be done.
- disintegrant examples include cellulose derivatives such as low-substituted hydroxypropyl cellulose, carboxymethyl cellulose, carboxymethyl cellulose calcium or carboxymethyl cellulose sodium; crosslinked polyvinylpyrrolidone; carboxymethyl starch or carboxymethyl starch sodium. Such chemically modified starches and celluloses can be mentioned.
- the component used as an excipient in the present invention can also be used as a disintegrant.
- the amount of valemetostat or a pharmaceutically acceptable salt to be incorporated in the pharmaceutical composition is not particularly limited, but for example, 10 to 10 to 10 to 10% of the uncoated tablet mass before coating. 75% by mass (7 to 55% by mass as valemetostat) or 25 to 60% by mass (20 to 45% by mass as valemetostat) may be blended.
- the amount of additives in the pharmaceutical composition is not particularly limited. 0.5 to 5% by mass), and 0.1 to 10% by mass (preferably 0.5 to 5% by mass) of a binder may be added.
- the pharmaceutical composition of the present invention includes, for example, tablets (including sublingual tablets and orally disintegrating agents), capsules (including soft capsules and microcapsules), granules, fine granules, powders, pills, chewables or Solid formulations such as lozenges can be used. Powders, fine granules, granules, capsules or tablets are preferred, and tablets are more preferred.
- the tablet which is one embodiment of the present invention, is film-coated to form a film-coated tablet.
- a film-coated tablet according to the present invention can have excellent dissolution properties and excellent storage stability.
- Coating is performed, for example, using a pan coating machine, and the film coating base includes, for example, a sugar coating base, a water-soluble film coating base, an enteric film coating base, a sustained release film coating base, or the like. can be mentioned.
- White sugar is used as the coating base, and one or a combination of two or more selected from talc, precipitated calcium carbonate, calcium phosphate, calcium sulfate, gelatin, gum arabic, polyvinylpyrrolidone, pullulan and the like can also be used. .
- Water-soluble film coating substrates include, for example, cellulose derivatives such as hydroxypropylcellulose, hypromellose, hydroxyethylcellulose, hydroxypropylcellulose, methylhydroxyethylcellulose or sodium carboxymethylcellulose; polyvinyl acetal diethylaminoacetate, aminoalkyl methacrylate copolymers, polyvinyl alcohol, Synthetic polymers such as polyvinyl alcohol/acrylic acid/methyl methacrylate copolymer or polyvinylpyrrolidone; polysaccharides such as pullulan;
- Enteric film coating substrates include, for example, cellulose derivatives such as hydroxypropylmethylcellulose phthalate, hydroxypropylmethylcellulose acetate succinate, carboxymethylethylcellulose or cellulose acetate phthalate; (meth)acrylic acid copolymer L, (meth)acrylic acid Acrylic acid derivatives such as copolymer LD or (meth)acrylic acid copolymer S; polyvinyl alcohol; polyvinyl alcohol/acrylic acid/methyl methacrylate copolymer; and natural products such as shellac.
- cellulose derivatives such as hydroxypropylmethylcellulose phthalate, hydroxypropylmethylcellulose acetate succinate, carboxymethylethylcellulose or cellulose acetate phthalate
- (meth)acrylic acid copolymer L (meth)acrylic acid Acrylic acid derivatives such as copolymer LD or (meth)acrylic acid copolymer S
- polyvinyl alcohol polyvinyl alcohol/acrylic acid/methyl me
- sustained release film coating substrates include cellulose derivatives such as ethyl cellulose; acrylic acid derivatives such as aminoalkyl methacrylate copolymer RS or ethyl acrylate/methyl methacrylate/copolymer emulsion. can.
- Preferred film-coating bases in the present invention are water-soluble film-coating bases. More preferably, it is one or more film coating bases selected from hypromellose, polyvinyl alcohol and polyvinyl alcohol/acrylic acid/methyl methacrylate copolymer.
- Two or more types of film coating bases may be mixed in an appropriate ratio and used.
- it may contain appropriate pharmaceutically acceptable plasticizers, excipients, lubricants, masking agents, coloring agents and/or preservatives.
- Diethyl acid and triethyl citrate, lauric acid, sucrose, dextrose, sorbitol, triacetin, acetyltriethyltitrate, triethyltitrate, tributyltitrate or acetyltributyltitrate and the like can be mentioned.
- Examples of the masking agent that can be incorporated into the film coating base of the present invention include titanium oxide and the like.
- the film coating base of the present invention may contain other ingredients such as talc.
- coloring agents examples include iron sesquioxide, yellow iron sesquioxide, black iron oxide, titanium oxide, Brilliant Blue FCF, Indigo carmine, and Red No. 3. (Erythrosine), Yellow No. 4 (Tartrazine), Yellow No. 5 (Sunset Yellow FCF) and the like. Iron sesquioxide, yellow iron sesquioxide, or black iron oxide is preferable, and iron sesquioxide or yellow iron sesquioxide is more preferable.
- Croscarmellose sodium can be added to the capsules of the present invention.
- Croscarmellose sodium that can be used includes Primellose (registered trademark) (DFEPharma) and the like.
- One or more lubricants can be added to the capsules of the present invention.
- a lubricant commonly used for oral solid preparations can be used as long as it exhibits excellent dissolution, but it is preferable to use sodium fumarate stearate.
- Partially pregelatinized starch can be blended into the capsules of the present invention.
- Partially pregelatinized starch that can be used includes Starch 1500G manufactured by Nippon Colorcon, PCS (registered trademark) PC-10 manufactured by Asahi Kasei, and the like.
- a fluidizing agent can be added to the capsules of the present invention for the purpose of improving fluidity of mixed powder or improving disintegration/dispersibility.
- fluidizing agents include light anhydrous silicic acid.
- the solid preparation of the present invention comprises a powder of the active ingredient valemetostat or a pharmaceutically acceptable salt thereof, (1) Add croscarmellose sodium, sodium starch glycolate, excipients, disintegrants, etc., and auxiliary agents (lubricants, etc.) necessary for formulation, (2) Tablets and surface-coated tablets can be obtained by directly compressing them.
- (3) or (1) is made into a granular powder by a dry granulation method or a wet granulation method, and other ingredients are added as appropriate, (4) a capsule filling step of compressing and filling the obtained granular powder with a capsule filling machine; (5) Alternatively, a tableting step of compressing the obtained granular powder with a tableting machine, (6) and, optionally, a coating step of coating the surface of the obtained granular powder, granules or tablets; can be obtained as powders, granules, surface-coated granules, capsules, tablets, and surface-coated tablets.
- Solid formulations can be manufactured by (1) a direct compression method in which the active ingredient and additives are mixed and directly compressed using a tableting machine, and (2) a semi-process in which the additives are granulated, mixed with the drug, and then compressed.
- Direct compression method (3) Dry granules in which the active ingredient and additives are granulated together, partially separately, or completely separately as granules by a dry method, and then optionally mixed with granules and lubricants and compression molded.
- Compression method (4) Wet granule compression method in which the active ingredient and additives are granulated together or partially separately as granules by a wet method, a lubricant and the like are added, and compression molding is performed.
- the granulation method means such as a fluidized granulation method, a high-speed agitation granulation method, and a melting granulation method can be used.
- the production method in the present invention is preferably a direct compression method, or a method in which the active ingredient and additives are granulated as granules by a dry method or a wet method, and then a lubricant or the like is added as necessary and compression molding is performed. .
- the lubricant may be added before granulation.
- Valemetostat as an active ingredient or a pharmaceutically acceptable salt thereof is pulverized to adjust the particle size, and then any one or more of croscarmellose sodium and sodium starch glycolate, and excipients , a binder disintegrant and a lubricant are granulated as granules by a dry method. Thereafter, the granules are compressed with a tableting machine to obtain tablets.
- the active ingredient valemetostat or a pharmaceutically acceptable salt thereof is pulverized to adjust the particle size, and then any one of croscarmellose sodium and sodium starch glycolate is added.
- the seeds, excipients, binders and/or disintegrants are granulated as granules by a wet method. After that, a lubricant is added, and the mixture is further mixed and then compressed with a tableting machine to obtain tablets.
- the compression pressure in tablet production is affected by the tablet size, so it is difficult to generalize. , 12 kN to 24 kN. Quality can be ensured by specifying the hardness and density as necessary.
- evaluation can also be performed at 60°C for one week or at 40°C/75% RH open conditions for one week so that short-term evaluation is possible.
- the dissolution of the pharmaceutical composition after storage at the temperature, humidity and storage period is more steady than the dissolution after storage at 40 ° C./75% RH for 3 months or 6 months. Usable if indicated to be low.
- the dosage of valemetostat or a pharmaceutically acceptable salt to be blended in the present invention may vary depending on various conditions such as drug activity, patient's symptoms, age or body weight.
- the dosage is usually 25 mg (as valemetostat) as a lower limit and 500 mg (as valemetostat) as an upper limit per day for adults. .
- Valemetostat tosilate, light anhydrous silicic acid, and sodium stearyl fumarate were mixed in a mortar at the ratios shown in Table 1-1 to obtain a mixed powder.
- Mixed powder, pregelatinized starch, and low-substituted hydroxypropyl cellulose were mixed in a mortar for 2 minutes according to the ratio shown in Table 1-1, and then sieved through a sieve with an opening of 500 ⁇ m to obtain sieved powder.
- 500 mg of the sieved powder was filled in a mortar of ⁇ 15 mm, compression-molded with a pressure of 20 kN, and crushed with a tablet grinder to obtain granules.
- 320 mg of granules were filled in a ⁇ 9 mm die and compressed under a pressure of 10 kN to obtain tablets.
- Example 1 Balemetostat tosilate, sodium stearyl fumarate, and light anhydrous silicic acid were weighed out in proportions shown in Table 1-2 and mixed in a mortar for 3 minutes to obtain a mixed powder. 500 mg of the mixed powder was filled in a mortar of ⁇ 15 mm, compression-molded with a pressure of 20 kN, and crushed with a tablet grinder to obtain granules. Granules and croscarmellose sodium were weighed out at the ratios shown in Table 1-2 and mixed for 30 seconds to obtain granules for tableting. 191.8 mg of granules for tableting were filled in a ⁇ 8 mm die and compressed under a pressure of 13 kN to obtain tablets.
- Example 2 Granules were obtained in the same manner as in Example 1. The granules, croscarmellose sodium, and sodium starch glycolate were mixed at the respective ratios shown in Tables 1-2 to prepare granules for tableting. 239.8 mg of granules for tableting were filled in a ⁇ 9 mm die and compressed under a pressure of 14 kN to obtain tablets.
- Example 3 Tablets were obtained in the same manner as in Comparative Example 2 at the ratios shown in Table 1-2.
- Example 4 Tablets were obtained in the same manner as in Comparative Example 2 at the ratios shown in Table 1-2. However, the compression pressure was set to 14 kN.
- Example 5 Tablets were obtained by the method according to Comparative Example 6 at the ratios shown in Table 1-2.
- Example 6 Balemetostat tosilate, light anhydrous silicic acid, and sodium stearyl fumarate were weighed out at the ratios shown in Table 1-2, mixed in a plastic bag for 1 minute, and then sieved through a sieve with an opening of 500 ⁇ m to obtain a mixed powder.
- Got an A Using a roller compactor (Freund Corporation, TF-mini), the mixed powder A was compressed at a roll pressure of 7 MPa and a roll rotation speed of 2.5 rpm, and then ⁇ 0 using Comil (Quadro, QC-197).
- Granules A were obtained by pulverizing with a .813 mm screen.
- Microcrystalline cellulose and croscarmellose sodium were weighed out at the ratios shown in Table 1-2 and mixed in a V-type mixer for 10 minutes to obtain mixed powder B.
- the mixed powder B was compressed at a roll pressure of 7 MPa and a roll rotation speed of 2.5 rpm, and then ⁇ 1 using Comil (Quadro, QC-197).
- Granules B were obtained by pulverizing with a screen of 0.575 mm. A fraction of granules B that passed through a sieve with an opening of 850 ⁇ m and remained on a sieve with an opening of 150 ⁇ m was designated as granules B′.
- Granules A and B' were mixed in a V-type mixer for 10 minutes to obtain granules for tableting. 450 mg of granules for tableting were filled in a die having a major diameter of 14 mm and a minor diameter of 6.5 mm, and were compressed under a pressure of 15 kN to obtain tablets.
- Example 7 Each component was weighed out at the ratio shown in Table 1-2, mixed with a V-type mixer for 10 minutes, and then sieved to obtain a mixed powder. Using a tableting machine (manufactured by Kikusui Seisakusho, Vela), 100 to 200 mg of the mixed powder is filled into a die of ⁇ 9.5 mm, and compression molded with a flat-cornered punch at a pressure of 8 to 10 kN to give slug tablets. Obtained. Using Comil (manufactured by Quadro, QC-197), the slug tablets were pulverized with a screen of ⁇ 0.991 mm to obtain granules. 231 mg of the granules were filled in a ⁇ 8.5 mm die and compressed under a pressure of 14 kN to obtain tablets.
- a tableting machine manufactured by Kikusui Seisakusho, Vela
- 100 to 200 mg of the mixed powder is filled into a die of ⁇ 9.5 mm, and compression
- Example 8 Tablets were obtained in the same manner as in Comparative Example 2 at the ratios shown in Table 1-2.
- Example 9 Granules were produced in the same manner as in Example 1. The granules and sodium starch glycolate were mixed at the ratios shown in Tables 1-3 to obtain granules for tableting. 264.8 mg of granules for tableting were filled in a ⁇ 9 mm die and compressed under a pressure of 11 kN to obtain tablets.
- Example 10 Tablets were obtained by the method according to Comparative Example 6 at the ratios shown in Table 1-3.
- the compression pressure was 7 kN.
- Example 11 Tablets were obtained by the method according to Comparative Example 6 at the ratios shown in Table 1-3.
- Example 12 Each component was weighed out at the ratio shown in Table 1-3 and mixed with a high-speed stirring granulator to obtain a mixed powder. Using a roller compactor (Freund Corporation, TF-mini), the mixed powder was compressed at a roll pressure of 5.5 MPa and a roll rotation speed of 2.5 rpm, and then using a power mill (Dalton, P-02S). The powder was pulverized with a screen of ⁇ 1 mm to obtain granules.
- a tableting machine (Virgo01 manufactured by Kikusui Seisakusho Co., Ltd.), 420 mg of granules were filled in a die having a major diameter of 14 mm and a minor diameter of 6.5 mm, and were compression-molded at a pressure of 18 kN to obtain uncoated tablets.
- a coating machine manufactured by Freund Corporation, Hi-Coater Labo
- one uncoated tablet was film-coated with about 20 mg of the film-coating agent to obtain film-coated tablets.
- the amount of film coating per tablet was determined from the difference in mass between 10 or 20 film-coated tablets before and after film coating. The same applies to the following examples.
- Example 13 Uncoated tablet components were weighed out at the ratios shown in Table 2, and uncoated tablets were obtained in the same manner as in Example 12. Using a coating machine (manufactured by Freund Corporation, Hi-Coater Labo), each uncoated tablet was film-coated with about 20 mg of film-coating agent to obtain film-coated tablets.
- Example 14 The uncoated tablet components were weighed out at the ratios shown in Table 2 and mixed with a V-type mixer for 10 minutes to obtain a mixed powder. Using a roller compactor (TF-mini manufactured by Freund Corporation), compression molding was performed at a pressure of 7 MPa and a roll rotation speed of 2.5 revolutions per minute to obtain granules. Using Comil (manufactured by Quadro, QC-U-5), the granules were pulverized with a screen of ⁇ 0.991 mm to obtain granules for tableting. 320 mg of granules for tableting were filled in a die of ⁇ 9 mm and compression molded at a pressure of 10 kN to obtain uncoated tablets. Using a coating machine (Hicoater FZ manufactured by Freund Corporation), each uncoated tablet was film-coated with about 10 mg of the film-coating agent to obtain film-coated tablets. The composition of Example 14 is also shown in Table 4 for reference.
- Example 15 The uncoated tablet components were weighed out at the ratios shown in Table 2 and mixed in a mortar to obtain a mixed powder. 500 mg of the mixed powder was filled in a mortar of ⁇ 15 mm, compression-molded with a pressure of 20 kN, and crushed with a tablet grinder to obtain granules. 420 mg of granules were filled in a die with a major diameter of 14 mm and a minor diameter of 6.5 mm, and compression-molded under a pressure of 11 kN to obtain uncoated tablets. Using a coating machine (PRC-GTX mini manufactured by Powrex), each uncoated tablet was film-coated with about 20 mg of the film-coating agent to obtain film-coated tablets.
- PRC-GTX mini manufactured by Powrex
- Example 16 Uncoated tablet components were weighed out at the ratios shown in Table 2, and uncoated tablets were obtained in the same manner as in Example 12. The film coating components were weighed out at the ratio shown in Table 2, dissolved and suspended in water to obtain a film coating solution. Using a coating machine (PRC-GTX mini manufactured by Powrex), each uncoated tablet was film-coated with about 26 mg of the film-coating agent to obtain film-coated tablets.
- Example 17 Uncoated tablet components were weighed out at the ratios shown in Table 2, and uncoated tablets were obtained in the same manner as in Example 12. However, the screen of the power mill used ⁇ 2 mm. The film coating components were weighed out at the ratio shown in Table 2, dissolved and suspended in water to obtain a film coating solution. Using a coating machine (Freund Corporation, Hi-Coater Labo), each uncoated tablet was film-coated with about 24 mg of the film-coating agent to obtain film-coated tablets.
- Example 18 The uncoated tablet components were weighed out at the ratios shown in Table 2 and mixed for 10 minutes using a high-speed stirring granulator to obtain a mixed powder.
- a tableting machine Karlin, a tableting machine, a tableting machine, a tableting machine (Kikusui Seisakusho, Virgo01)
- 300 mg of the mixed powder was filled into a ⁇ 15 mm die, and compression molded at a pressure of 20 kN. to obtain granules.
- a tableting machine (Virgo01 manufactured by Kikusui Seisakusho)
- 420 mg of granules were filled into a die having a major diameter of 14 mm and a minor diameter of 6.5 mm, and were compression-molded at a pressure of 19 kN to obtain uncoated tablets.
- a coating machine manufactured by Freund Corporation, Hi-Coater Labo
- each uncoated tablet was film-coated with about 21 mg of the film-coating agent to obtain film
- Example 19 The uncoated tablet components were weighed out at the ratios shown in Table 2 and mixed for 10 minutes using a high-speed stirring granulator to obtain a mixed powder. After compression molding using a roller compactor (Freund Corporation, TF-mini) at a pressure of 7 MPa and a roll rotation speed of 2.5 rpm, a ⁇ 0.991 mm screen was formed using a Comil (Quadro, U-5). to obtain granules.
- a roller compactor Frund Corporation, TF-mini
- a tableting machine (Virgo01 manufactured by Kikusui Seisakusho) 420 mg of granules were filled into a die having a major diameter of 14 mm and a minor diameter of 6.5 mm, and were compression-molded at a pressure of 19 kN to obtain uncoated tablets.
- a coating machine manufactured by Freund Corporation, Hi-Coater Labo
- each uncoated tablet was film-coated with about 21 mg of the film-coating agent to obtain film-coated tablets.
- Example 20 Uncoated tablet components were weighed out at the ratios shown in Table 2, and uncoated tablets were obtained in the same manner as in Example 12. A screen of ⁇ 2 mm was used for the power mill. The film coating components were weighed out at the ratio shown in Table 2, dissolved and suspended in water to obtain a film coating solution. Using a coating machine (Freund Corporation, Hi-Coater Labo), each uncoated tablet was film-coated with about 20 mg of the film-coating agent to obtain film-coated tablets.
- Example 21 The uncoated tablet components were weighed out at the ratios shown in Table 3 and mixed with a high-speed stirring granulator to obtain a mixed powder. Using a roller compactor (Freund Corporation, FP90 x 30), the mixed powder was compression molded at a roll pressure of 17.5 MPa and a roll rotation speed of 8 rpm, and then crushed using a crusher attached to the roller compactor. , to obtain granules.
- Example 22 Uncoated tablet components were weighed out at the ratios shown in Table 3, and uncoated tablets were obtained in the same manner as in Example 12. However, the screen of the power mill used ⁇ 2 mm. The film coating components were weighed out at the ratio shown in Table 3, dissolved and suspended in water to obtain a film coating solution. Using a coating machine (Freund Corporation, Hi-Coater Labo), each uncoated tablet was film-coated with about 16 mg of film-coating agent to obtain film-coated tablets.
- Example 23 Using the uncoated tablet of Example 22 and the film coating liquid, film coating was carried out in the same manner. About 28 mg of film-coating agent was film-coated on one uncoated tablet to obtain a film-coated tablet.
- Example 24 Uncoated tablet components were weighed out at the ratios shown in Table 4, and granules were obtained in the same manner as in Example 19. 105 mg of granules were filled in a mortar of ⁇ 6.5 mm and compression-molded with a pressure of 9 kN to obtain uncoated tablets. Using a coating machine (manufactured by Freund Corporation, Hi-Coater Labo), each uncoated tablet was film-coated with about 5 mg of film-coating agent to obtain film-coated tablets.
- Example 25 Uncoated tablet components were weighed out at the ratios shown in Table 4, and granules were obtained in the same manner as in Example 21. However, it was manufactured under the conditions of a roll pressure of 19 MPa and a roll rotation speed of 11.5 revolutions per minute. 210 mg of granules were filled in a ⁇ 8 mm die and compressed with a tableting pressure of 13 kN to obtain uncoated tablets. Using a coating machine (PRC-GTX mini manufactured by Powrex), each uncoated tablet was film-coated with about 10 mg of the film-coating agent to obtain film-coated tablets.
- PRC-GTX mini manufactured by Powrex
- Example 26 Uncoated tablet components were weighed out at the ratios shown in Table 4, and granules were obtained in the same manner as in Comparative Example 6. 462 mg of granules were filled in a die with a major diameter of 14 mm and a minor diameter of 6.5 mm, and compression molded at a pressure of 15 kN to obtain uncoated tablets.
- Test Example 1 Dissolution Test Using Uncoated Tablets
- the mortar of Comparative Example 1 was fixed to a shaft by the rotating basket method described in the Japanese Pharmacopoeia.
- An apparatus described in the dissolution test method of the Japanese Pharmacopoeia was used for the dissolution test.
- the upper part of the powder surface of the compression-molded product was kept out of contact with the test solution, and the lower part of the powder surface was in contact with the test solution.
- 900 mL of the Japanese Pharmacopoeia Dissolution Test Liquid 2 is added, and while rotating the die at 50 rpm, the ballet from the compression molded product is removed.
- the amount of stat elution was determined from the absorbance of the test solution by ultraviolet spectroscopy (measurement wavelength 295 nm, control 360 nm) (The method for evaluating the drug elution rate from the powder surface is described in "Pharmaceutical Kinetics" by Tsuki Yamana. (see Methods).
- the paddle method described in the Japanese Pharmacopoeia Dissolution Test Method was used in 900 mL of the Japanese Pharmacopoeia Dissolution Test 2nd Fluid at 50 rpm. was performed, and the absorbance of the test solution was measured by ultraviolet spectroscopy (measurement wavelength: 295 nm, control: 360 nm, or 297 nm) to measure the dissolution rate. Table 5 shows the results.
- the tablets of Comparative Examples 1-6 had an extremely low dissolution rate of valemetostat tosilate. A translucent low-solubility substance was formed in the part in contact with the test solution, and the inside was dry. It was suggested. By blending croscarmellose sodium and/or sodium starch glycolate, the tablets of Examples 1 to 12 did not produce low-soluble substances and had a high dissolution rate of 73 to 101% 60 minutes after the start of the test. found to improve.
- Test Example 2 Stability and dissolution test 1 using film-coated tablets
- the uncoated tablet and film-coated tablet described in Example 13 were placed in a plastic bottle (manufactured by Gerresheimer, DUMA TWIST-OFF, volume 50 mL), used as a stability test sample, and stored in a constant temperature bath at 60°C for 1 week.
- each of the pharmaceutical compositions of Example 13 was packaged in a PTP and used as a stability test specimen. Stability test specimens were stored in a constant temperature bath at 40°C/75% RH for 3 months.
- the film-coated tablet (FC tablet) described in Example 13 showed good quality even after storage compared to the uncoated tablet.
- Test Example 3 Stability and dissolution test 2 using film-coated tablets
- the uncoated tablets and film-coated tablets described in Examples 14, 15, 17 and 20 were placed in plastic bottles (manufactured by Gerresheimer, DUMA TWIST-OFF, volume 50 mL) and used as stability test specimens.
- the film-coated tablet of Example 16 was PTP-packaged, the PTP sheet was placed in an aluminum bag and sealed to obtain a stability test sample.
- the film-coated tablets of Examples 18 and 19 were placed in plastic bottles (TCB, No. 4, manufactured by Taisei Kako Co., Ltd.) and used as stability test specimens.
- Each stability test specimen was stored in a constant temperature bath at 60°C for 1 week and in a constant temperature bath at 40°C/75% RH for 4 weeks, 3 months, or 6 months.
- the paddle method described in the Japanese Pharmacopoeia dissolution test method was used to perform the dissolution test at 50 rpm in 900 mL of the Japanese Pharmacopoeia dissolution test liquid 2.
- the absorbance was measured by ultraviolet spectroscopy (measurement wavelength 295 nm, control 360 nm, or 297 nm) to measure the dissolution rate. The results are shown in Tables 7, 8 and 9.
- Test Example 4 Stability and dissolution test 3 using film-coated tablets
- the uncoated tablet and film-coated tablet of Example 21 were placed in a plastic bottle (manufactured by Gerresheimer, DUMA TWIST-OFF, volume 50 mL) and stored in a constant temperature bath at 60°C for 12 days.
- the PTP sheet was sealed in an aluminum bag and stored in a constant temperature bath at 60°C for 1 week.
- the paddle method described in the Japanese Pharmacopoeia dissolution test method was used to perform the dissolution test at 50 rpm in 900 mL of the Japanese Pharmacopoeia dissolution test liquid 2.
- the absorbance at a wavelength of 297 nm was measured by ultraviolet spectroscopy to measure the dissolution rate. The results are shown in Tables 10 and 11.
- Example 5 Dissolution test at various contents and blending ratios
- the tablets described in Examples 24, 25, 14 and 26 were subjected to the paddle method described in the Japanese Pharmacopoeia dissolution test method, and 900 mL of the Japanese pharmacy Dissolution test A dissolution test was performed at 50 revolutions per minute in the second fluid.
- the absorbance at a wavelength of 297 nm was measured by ultraviolet spectroscopy to measure the dissolution rate.
- the absorbance of the test solution was measured by ultraviolet spectroscopy (measurement wavelength: 295 nm, control: 360 nm) to determine the dissolution rate. Table 12 shows the results. All examples showed good dissolution properties.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Inorganic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Description
バレメトスタットは次の構造式:
(2)更に水不溶性賦形剤を含む(1)に記載の医薬組成物。
(3)水不溶性賦形剤が、結晶セルロース、部分アルファー化デンプン、及びアルファー化デンプンから選ばれるいずれか1種以上である(2)に記載の医薬組成物。
(4)水不溶性賦形剤が、結晶セルロースである(2)又は(3)に記載の医薬組成物。
(5)医薬組成物の全質量に対して5~25質量%のクロスカルメロースナトリウムを含む(1)~(4)のいずれか1つに記載の医薬組成物。
(6)医薬組成物の全質量に対して5~45質量%のデンプングリコール酸ナトリウムを含む(1)~(5)のいずれか1つに記載の医薬組成物。
(7)更に1種以上の滑沢剤を含む(1)~(6)のいずれか1つに記載の医薬組成物。
(8)錠剤である(1)~(7)のいずれか1つに記載の医薬組成物。
(9)フィルムコーティング錠である(8)に記載の医薬組成物。
(10)フィルムコーティング成分がヒプロメロース、ポリビニルアルコール及びポリビニルアルコール・アクリル酸・メタクリル酸メチル共重合体から選ばれる1種以上である(9)に記載の医薬組成物。
(1)クロスカルメロースナトリウム、デンプングリコール酸ナトリウム、賦形剤及び崩壊剤等、さらに製剤化に必要な助剤(滑沢剤等)を添加して、
(2)これを直接打錠することにより錠剤、表面コート錠剤を得ることができる。
(3)あるいは(1)を乾式造粒法あるいは湿式造粒法により粒状粉末として適宜他成分を添加し、
(4)得られた粒状粉末をカプセル充填機によって圧縮充填するカプセル充填工程、
(5)または、得られた粒状粉末を打錠機によって圧縮する錠剤化工程、
(6)そして必要に応じて、得られた粒状粉末、顆粒または錠剤の表面をコーティングするコーティング工程、
を順次おこなうことによって、散剤、顆粒剤、表面コート顆粒剤、カプセル剤、錠剤、表面コート錠剤として得ることができる。
バレメトスタットトシル酸塩約270mgをφ10mmの臼に充填し、1tonの圧力で圧縮成型した。成型物を臼から排出しなかった。
表1-1に示す比率にて、バレメトスタットトシル酸塩、軽質無水ケイ酸、フマル酸ステアリルナトリウムを乳鉢で混合し、混合末を得た。表1-1に示す比率に従い、混合末、アルファー化デンプン、低置換度ヒドロキシプロピルセルロースを乳鉢で2分間混合した後、目開き500μmの篩で篩過し、篩過末を得た。篩過末500mgをφ15mmの臼に充填し、20kNの圧力で圧縮成型した後、錠剤粉砕機で解砕し、顆粒を得た。顆粒320mgをφ9mmの臼に充填し、10kNの圧力で圧縮成型し、錠剤を得た。
表1-1に示す比率にて、比較例2に準じた方法にて、錠剤を得た。
表1-1に示す比率にて、比較例2に準じた方法にて、錠剤を得た。
表1-1に示す比率にて、比較例2に準じた方法にて、錠剤を得た。
表1-1に示す比率にて、各成分を量り取り乳鉢で2分間混合した後、目開き500μmの篩で篩過し、混合末を得た。比較例2に準じた方法にて顆粒及び錠剤を得た。
表1-2に示す割合にてバレメトスタットトシル酸塩、フマル酸ステアリルナトリウム、軽質無水ケイ酸を量り取り、乳鉢で3分間混合し、混合末を得た。混合末500mgをφ15mmの臼に充填し、20kNの圧力で圧縮成型した後、錠剤粉砕機で解砕し、顆粒を得た。表1-2に示す割合にて顆粒とクロスカルメロースナトリウムを量り取った後30秒間混合し、打錠用顆粒を得た。打錠用顆粒191.8mgをφ8mmの臼に充填し13kNの圧力で圧縮成型し、錠剤を得た。
実施例1に準じた方法にて、顆粒を得た。顆粒、クロスカルメロースナトリウム、及びデンプングリコール酸ナトリウムを、それぞれ表1―2に示した比率にて混合し、打錠用顆粒を製した。打錠用顆粒239.8mgをφ9mmの臼に充填し14kNの圧力で圧縮成型し、錠剤を得た。
表1-2に示す比率にて、比較例2に準じた方法にて、錠剤を得た。
表1-2に示す比率にて、比較例2に準じた方法にて、錠剤を得た。ただし、圧縮圧力を14kNとした。
表1-2に示す比率にて、比較例6に準じた方法にて、錠剤を得た。
表1-2に示す比率にてバレメトスタットトシル酸塩、軽質無水ケイ酸、フマル酸ステアリルナトリウムを量り取り、ポリ袋で1分間混合した後、目開き500μmの篩で篩過し、混合末Aを得た。ローラーコンパクター(フロイント産業製、TF-mini)を用いて、混合末Aをロール圧力7MPa、ロール回転速度毎分2.5回転で圧縮した後、コーミル(クアドロ製、QC-197)を用いてφ0.813mmのスクリーンにて解砕し、顆粒Aを得た。
表1-2に示す比率にて結晶セルロース及びクロスカルメロースナトリウムを量り取り、V型混合機で10分間混合し、混合末Bを得た。ローラーコンパクター(フロイント産業製、TF-mini)を用いて、混合末Bをロール圧力7MPa、ロール回転速度毎分2.5回転で圧縮した後、コーミル(クアドロ製、QC-197)を用いてφ1.575mmのスクリーンにて解砕し、顆粒Bを得た。顆粒Bのうち、目開き850μmの篩を通過し、目開き150μmの篩上に残った分画を顆粒B´とした。
顆粒Aと顆粒B´をV型混合機で10分間混合し、打錠用顆粒を得た。打錠用顆粒450mgを長径14mm短径6.5mmの臼に充填し、15kNの圧力で圧縮成型し、錠剤を得た。
表1-2に示す比率にて各成分を量り取り、V型混合機で10分間混合した後篩過し、混合末を得た。打錠機(菊水製作所製、Vela)を用いて、混合末100~200mgをφ9.5mmの臼に充填し、平隅角の杵により、圧力8~10kNの圧力で圧縮成型し、スラッグ錠を得た。コーミル(クアドロ製、QC-197)を用いて、スラッグ錠をφ0.991mmのスクリーンにて解砕し、顆粒とした。顆粒231mgをφ8.5mmの臼に充填し14kNの圧力で圧縮成型し、錠剤を得た。
表1-2に示す比率にて、比較例2に準じた方法にて、錠剤を得た。
実施例1に準じた方法にて、顆粒を作製した。顆粒及びデンプングリコール酸ナトリウムを、それぞれ表1-3に示した比率にて混合し、打錠用顆粒を得た。打錠用顆粒264.8mgをφ9mmの臼に充填し11kNの圧力で圧縮成型し、錠剤を得た。
表1-3に示す比率にて、比較例6に準じた方法にて、錠剤を得た。圧縮圧力は7kNとした。
表1-3に示す比率にて、比較例6に準じた方法にて、錠剤を得た。
表1-3に示す比率にて各成分を量り取り、高速攪拌造粒機で混合し、混合末を得た。ローラーコンパクター(フロイント産業製、TF-mini)を用いて、混合末をロール圧力5.5MPa、ロール回転速度毎分2.5回転で圧縮した後、パワーミル(ダルトン製、P-02S)を用いてφ1mmのスクリーンにて解砕し、顆粒を得た。打錠機(菊水製作所製、Virgo01)を用いて、顆粒420mgを長径14mm短径6.5mmの臼に充填し、18kNの圧力で圧縮成型し、素錠を得た。コーティング機(フロイント産業製、ハイコーターラボ)を用いて、素錠1錠にフィルムコーティング剤約20mgをフィルムコーティングし、フィルムコーティング錠を得た。1錠あたりのフィルムコーティング量は、フィルムコーティング前後のフィルムコーティング錠10錠または20錠の質量差から求めた。以下の実施例においても同様である。
表2に示す比率にて素錠成分を量り取り、実施例12に準じた方法にて素錠を得た。コーティング機(フロイント産業製、ハイコーターラボ)を用いて、素錠1錠あたり約20mgのフィルムコーティング剤をフィルムコーティングし、フィルムコーティング錠を得た。
表2に示す比率にて素錠成分を量り取り、V型混合機で10分間混合し、混合末を得た。ローラーコンパクター(フロイント産業製、TF-mini)を用いて、圧力7MPa、ロール回転速度毎分2.5回転で圧縮成型し、造粒物を得た。コーミル(クアドロ製、QC-U-5)を用いて、造粒物をφ0.991mmのスクリーンにて解砕し、打錠用顆粒とした。
打錠用顆粒320mgをφ9mmの臼に充填し10kNの圧力で圧縮成型し、素錠を得た。コーティング機(フロイント産業製、ハイコーターFZ)を用いて、素錠1錠あたり約10mgのフィルムコーティング剤をフィルムコーティングし、フィルムコーティング錠を得た。なお、実施例14については参照用に表4にも組成を記載した。
表2に示す比率にて素錠成分を量り取り、乳鉢で混合し、混合末を得た。混合末500mgをφ15mmの臼に充填し、20kNの圧力で圧縮成型した後、錠剤粉砕機で解砕し、顆粒を得た。顆粒420mgを長径14mm短径6.5mmの臼に充填し、11kNの圧力で圧縮成型し、素錠を得た。コーティング機(パウレック製、PRC―GTX mini)を用いて、素錠1錠あたり約20mgのフィルムコーティング剤をフィルムコーティングし、フィルムコーティング錠を得た。
表2に示す比率にて、素錠成分を量り取り、実施例12に準じた方法にて素錠を得た。
表2に示す比率にてフィルムコーティング成分を量り取り、水に溶解・懸濁し、フィルムコーティング液を得た。コーティング機(パウレック製、PRC―GTX mini)を用いて、素錠1錠あたり約26mgのフィルムコーティング剤をフィルムコーティングし、フィルムコーティング錠を得た。
表2に示す比率にて素錠成分を量り取り、実施例12に準じた方法にて素錠を得た。ただし、パワーミルのスクリーンはφ2mmを用いた。
表2に示す比率にてフィルムコーティング成分を量り取り、水に溶解・懸濁し、フィルムコーティング液を得た。コーティング機(フロイント産業製、ハイコーターラボ)を用いて、素錠1錠あたり約24mgのフィルムコーティング剤をフィルムコーティングし、フィルムコーティング錠を得た。
表2に示す比率にて素錠成分を量り取り、高速攪拌造粒機で10分間混合し、混合末を得た。打錠機(菊水製作所製、Virgo01)を用いて、混合末300mgをφ15mmの臼に充填し、20kNの圧力で圧縮成型した後、パワーミル(ダルトン製、P-02S)を用いてφ1mmのスクリーンにて解砕し、顆粒を得た。打錠機(菊水製作所製、Virgo01)を用いて、顆粒420mgを長径14mm短径6.5mmの臼に充填し、19kNの圧力で圧縮成型し、素錠を得た。
コーティング機(フロイント産業製、ハイコーターラボ)を用いて、素錠1錠あたり約21mgのフィルムコーティング剤をフィルムコーティングし、フィルムコーティング錠を得た。
表2に示す比率にて素錠成分を量り取り、高速攪拌造粒機で10分間混合し、混合末を得た。ローラーコンパクター(フロイント産業製、TF-mini)を用いて圧力7MPa、ロール回転速度毎分2.5回転で圧縮成型した後、コーミル(クアドロ製、U-5)を用いてφ0.991mmのスクリーンにて解砕し、顆粒を得た。打錠機(菊水製作所製、Virgo01)を用いて、顆粒420mgを長径14mm短径6.5mmの臼に充填し、19kNの圧力で圧縮成型し、素錠を得た。
コーティング機(フロイント産業製、ハイコーターラボ)を用いて、素錠1錠に約21mgのフィルムコーティング剤をフィルムコーティングし、フィルムコーティング錠を得た。
表2に示す比率にて素錠成分を量り取り、実施例12に準じた方法にて素錠を得た。パワーミルのスクリーンはφ2mmを用いた。
表2に示す比率にてフィルムコーティング成分を量り取り、水に溶解・懸濁し、フィルムコーティング液を得た。コーティング機(フロイント産業製、ハイコーターラボ)を用いて、素錠1錠に約20mgのフィルムコーティング剤をフィルムコーティングし、フィルムコーティング錠を得た。
表3に示す比率にて素錠成分を量り取り、高速攪拌造粒機で混合し、混合末を得た。ローラーコンパクター(フロイント産業製、FP90×30)を用いて、混合末をロール圧力17.5MPa、ロール回転速度毎分8回転で圧縮成型した後、ローラーコンパクターに付属の解砕機を用いて解砕し、顆粒を得た。打錠機(菊水製作所製、AQUC)を用いて、顆粒420mgを長径14mm短径6.5mmの臼に充填し、21kNの圧力で圧縮成型し、素錠を得た。
コーティング機(パウレック製、PRC-GTX mini)を用いて、素錠1錠に約2mgのフィルムコーティング剤をフィルムコーティングし、フィルムコーティング錠を得た。
表3に示す比率にて素錠成分を量り取り、実施例12に準じた方法にて素錠を得た。ただし、パワーミルのスクリーンはφ2mmを用いた。
表3に示す比率にてフィルムコーティング成分を量り取り、水に溶解・懸濁し、フィルムコーティング液を得た。コーティング機(フロイント産業製、ハイコーターラボ)を用いて、素錠1錠に約16mgのフィルムコーティング剤をフィルムコーティングし、フィルムコーティング錠を得た。
実施例22の素錠及びフィルムコーティング液を用いて、同様にフィルムコーティングを実施した。素錠1錠に約28mgのフィルムコーティング剤をフィルムコーティングし、フィルムコーティング錠を得た。
表4に示す比率にて素錠成分を量り取り、実施例19に準じた方法にて顆粒を得た。顆粒105mgをφ6.5mmの臼に充填し、9kNの圧力で圧縮成型し、素錠を得た。
コーティング機(フロイント産業製、ハイコーターラボ)を用いて、素錠1錠に約5mgのフィルムコーティング剤をフィルムコーティングし、フィルムコーティング錠を得た。
表4に示す比率にて素錠成分を量り取り、実施例21に準じた方法にて顆粒を得た。ただし、ロール圧力19MPa、ロール回転速度毎分11.5回転の条件で製造した。顆粒210mgをφ8mmの臼に充填し、打錠圧力13kNの圧縮し、素錠を得た。
コーティング機(パウレック製、PRC-GTX mini)を用いて、素錠1錠に約10mgのフィルムコーティング剤をフィルムコーティングし、フィルムコーティング錠を得た。
表4に示す比率にて素錠成分を量り取り、比較例6に準じた方法にて顆粒を得た。顆粒462mgを長径14mm短径6.5mmの臼に充填し、15kNの圧力で圧縮成型し、素錠を得た。
比較例1の臼を、日本薬局方に記載された回転バスケット法の要領でシャフトに固定した。溶出試験には、日本薬局方溶出試験法に記載の装置を用いた。圧縮成型物の粉面上部は試験液に触れないようにし、粉面下部は試験液に触れるようにした。粉面下部がベッセルの底から約2cmとなるよう設置した後、900mLの日本薬局方溶出試験第2液中を加えて、毎分50回転で臼を回転させながら、圧縮成型物からのバレメトスタットの溶出量を、紫外分光法(測定波長295nm、対照360nm)により試験液の吸光度から求めた(粉体面からの薬物溶出速度の評価方法は、山名月中『医薬品速度論』に記載の方法を参照した)。
結果を表5に示す。
実施例13に記載の素錠及びフィルムコーティング錠を、プラスチックボトル(Gerresheimer製、DUMA TWIST―OFF 、容量50mL)に入れ、安定性試験検体とし、60℃の恒温槽に1週間保存した。また、実施例13の医薬組成物を、それぞれPTPに包装し、安定性試験検体とした。安定性試験検体を40℃/75%RHの恒温槽に3箇月間保存した。安定性試験開始時及び保存後の各安定性試験検体について、日本薬局方溶出試験法に記載されたパドル法にて、900mLの日本薬局方溶出試験第2液中で、毎分50回転の溶出試験を行い、紫外分光法(測定波長297nm)で試験液の吸光度を測定し、溶出率を測定した。結果を表6に示す。
実施例14、15、17及び20に記載の素錠及びフィルムコーティング錠を、それぞれプラスチックボトル(Gerresheimer製、DUMA TWIST―OFF 、容量50mL)に入れ、安定性試験検体とした。実施例16のフィルムコーティング錠をPTP包装した後、PTPシートをアルミ袋に入れ密封し、安定性試験検体とした。実施例18及び19のフィルムコーティング錠をプラスチックボトル(大成化工製、TCB、4号)に入れ、安定性試験検体とした。各安定性試験検体を、60℃の恒温槽に1週間、40℃/75%RHの恒温槽に4週間、3箇月間あるいは6箇月間保存した。安定性試験開始時品と、各保存後品について、日本薬局方溶出試験法に記載されたパドル法にて、900mLの日本薬局方溶出試験第2液中で、毎分50回転の溶出試験を行い、紫外分光法(測定波長295nm、対照360nm、または297nm)で吸光度を測定し、溶出率を測定した。結果を表7、8、9に示す。
実施例21の素錠及びフィルムコーティング錠をそれぞれプラスチックボトル(Gerresheimer製、DUMA TWIST―OFF 、容量50mL)に入れ、60℃の恒温槽に12日間保存した。実施例22及び23に記載のフィルムコーティング錠をそれぞれPTP包装した後、PTPシートをアルミ袋に入れ密封し、これを60℃の恒温槽に1週間保存した。安定性試験開始時品と、各保存後品について、日本薬局方溶出試験法に記載されたパドル法にて、900mLの日本薬局方溶出試験第2液中で、毎分50回転の溶出試験を行い、紫外分光法で波長297nmにおける吸光度を測定し、溶出率を測定した。結果を表10及び表11に示す。
実施例24、25、14及び26に記載された錠剤について、日本薬局方溶出試験法に記載されたパドル法にて、900mLの日本薬局方溶出試験第2液中で、毎分50回転の溶出試験を行った。実施例24及び25については紫外分光法で波長297nmにおける吸光度を測定し、溶出率を測定した。実施例14及び26については紫外分光法(測定波長295nm、対照360nm)で試験液の吸光度を測定し、溶出率を測定した。
結果を表12に示す。いずれの実施例も良好な溶出性を示した。
Claims (10)
- バレメトスタットまたは製薬学的に許容されるその塩、並びに、クロスカルメロースナトリウム及びデンプングリコール酸ナトリウムから選ばれるいずれか1種以上を含む医薬組成物。
- 更に水不溶性賦形剤を含む請求項1に記載の医薬組成物。
- 水不溶性賦形剤が、結晶セルロース、部分アルファー化デンプン、及びアルファー化デンプンから選ばれるいずれか1種以上である請求項2に記載の医薬組成物。
- 水不溶性賦形剤が、結晶セルロースである請求項2又は3に記載の医薬組成物。
- 医薬組成物の全質量に対して5~25質量%のクロスカルメロースナトリウムを含む請求項1~4のいずれか1項に記載の医薬組成物。
- 医薬組成物の全質量に対して5~45質量%のデンプングリコール酸ナトリウムを含む請求項1~5のいずれか1項に記載の医薬組成物。
- 更に1種以上の滑沢剤を含む請求項1~6のいずれか1項に記載の医薬組成物。
- 錠剤である請求項1~7のいずれか1項に記載の医薬組成物。
- フィルムコーティング錠である請求項8に記載の医薬組成物。
- フィルムコーティング成分がヒプロメロース、ポリビニルアルコール及びポリビニルアルコール・アクリル酸・メタクリル酸メチル共重合体から選ばれる1種以上である請求項9に記載の医薬組成物。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA3237792A CA3237792A1 (en) | 2021-11-10 | 2022-11-09 | Pharmaceutical composition having excellent dissolution properties |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2021183134 | 2021-11-10 | ||
JP2021-183134 | 2021-11-10 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2023085300A1 true WO2023085300A1 (ja) | 2023-05-19 |
Family
ID=86336118
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2022/041656 WO2023085300A1 (ja) | 2021-11-10 | 2022-11-09 | 優れた溶出性を有する医薬組成物 |
Country Status (3)
Country | Link |
---|---|
CA (1) | CA3237792A1 (ja) |
TW (1) | TW202333702A (ja) |
WO (1) | WO2023085300A1 (ja) |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2015141616A1 (ja) * | 2014-03-17 | 2015-09-24 | 第一三共株式会社 | 1,3-ベンゾジオキソール誘導体 |
JP2021091624A (ja) * | 2019-12-09 | 2021-06-17 | 沢井製薬株式会社 | ソラフェニブトシル酸塩製剤 |
-
2022
- 2022-11-09 CA CA3237792A patent/CA3237792A1/en active Pending
- 2022-11-09 WO PCT/JP2022/041656 patent/WO2023085300A1/ja active Application Filing
- 2022-11-09 TW TW111142745A patent/TW202333702A/zh unknown
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2015141616A1 (ja) * | 2014-03-17 | 2015-09-24 | 第一三共株式会社 | 1,3-ベンゾジオキソール誘導体 |
JP2021091624A (ja) * | 2019-12-09 | 2021-06-17 | 沢井製薬株式会社 | ソラフェニブトシル酸塩製剤 |
Also Published As
Publication number | Publication date |
---|---|
CA3237792A1 (en) | 2023-05-19 |
TW202333702A (zh) | 2023-09-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP6560289B2 (ja) | 新たな医薬組成物 | |
TWI635863B (zh) | 帕博西里之固態劑型 | |
JP5794650B2 (ja) | 難溶性薬物の溶解性改善製剤 | |
JP2019534887A (ja) | レナリドミドの経口用錠剤組成物 | |
US11529326B2 (en) | Eflornithine and sulindac, fixed dose combination formulation | |
WO2017075576A1 (en) | Eflornithine and sulindac, fixed dose combination formulation | |
TW201717937A (zh) | 含有芳基烷基胺化合物之醫藥組合物 | |
TW201818936A (zh) | 一種吡啶酮類衍生物醫藥組成物及其製備方法 | |
JP2015057422A (ja) | イルベサルタンを含有する錠剤 | |
JP2023071921A (ja) | 様々な用量のレナリドミドの経口用錠剤組成物 | |
JP2023036924A (ja) | レナリドミドを含む医薬組成物 | |
WO2023085300A1 (ja) | 優れた溶出性を有する医薬組成物 | |
JP2016037463A (ja) | ボリコナゾールを含む医薬組成物 | |
WO2017093890A1 (en) | Clobazam tablet formulation and process for its preparation | |
JP2022020459A (ja) | ニロチニブ錠剤 | |
JP5744412B2 (ja) | フロセミド製剤 | |
TW202038918A (zh) | 醫藥組合物 | |
CN118234494A (zh) | 具有优异溶出性质的药物组合物 | |
US9775832B2 (en) | Pharmaceutical composition for oral administration | |
TW201431553A (zh) | N-[5-[2-(3,5-二甲氧基苯基)乙基]-2h-吡唑-3-基]-4-[(3r,5s)-3,5-二甲基哌□-1-基]苯甲醯胺之醫藥調配物 | |
JP7133811B2 (ja) | 錠剤 | |
TWI810656B (zh) | 二氟甲基鳥氨酸及舒林酸(sulindac),固定劑量組合調配物 | |
US20130064890A1 (en) | Pharmaceutical formulation based on ibuprofen and codeine having improved stability | |
EP3251669B1 (en) | Solid composition of pyrrole carboxamide | |
TW202038912A (zh) | 難溶性藥物的固體分散體 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 22892798 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 2023559659 Country of ref document: JP Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 3237792 Country of ref document: CA |
|
REG | Reference to national code |
Ref country code: BR Ref legal event code: B01A Ref document number: 112024009008 Country of ref document: BR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2022892798 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 2022892798 Country of ref document: EP Effective date: 20240610 |